Skip to main content
ALLERGY THERAPEUTICS PLC logo

ALLERGY THERAPEUTICS PLC — Investor Relations & Filings

Ticker · AGY ISIN · GB00B02LCQ05 LEI · 213800PQ7AHK7KGVOE23 IL Manufacturing
Open in API
Filings indexed 416 across all filing types
Latest filing 2026-03-31 Interim / Quarterly Rep…
Country GB United Kingdom
Listing IL AGY

About ALLERGY THERAPEUTICS PLC

https://allergytherapeutics.com/

Allergy Therapeutics PLC is an immunology company focused on the research, development, diagnosis, and treatment of allergic disorders. The company specializes in creating therapies for allergy treatment and prevention, with a key focus on developing aluminum-free immunotherapies and allergy vaccines. These treatments aim to address the underlying cause of the allergy rather than merely managing symptoms. Leveraging its specialist expertise in immunology, the company strives to develop effective and convenient solutions to improve the quality of life for individuals with allergies.

Recent filings

Filing Released Lang Actions
Interim Results for six months ended 31 Dec 2025
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Interim Results for the six months ended 31 December 2025' and contains comprehensive financial statements, including a consolidated income statement and statement of comprehensive income, along with detailed management commentary on financial and operational performance. It is not a mere announcement of a report, but the report itself, containing substantive financial data for a period shorter than a full fiscal year. H1 2026
2026-03-31 English
PDMR Dealings & Shareholding Update
Director's Dealing Classification · 100% confidence The document is an official notification regarding changes in shareholding structure and transactions by a Person Discharging Managerial Responsibilities (PDMR). It explicitly details share transfers and sales involving ZQ Capital and a director (Zheqing Shen), including a table formatted for 'Notification and public disclosure of transactions by Director/PDMR'. While it mentions shareholding updates, the primary regulatory purpose is the disclosure of director/PDMR dealings, which falls under the DIRS category.
2026-03-12 English
Positive Biomarker Results from PROTECT Trial
Regulatory Filings Classification · 95% confidence The document is an official announcement from Allergy Therapeutics PLC regarding positive biomarker results from a clinical trial (PROTECT Phase I/IIa). It is distributed via the Regulatory News Service (RNS) of the London Stock Exchange. While it discusses clinical trial results, it does not fit into specific financial reporting categories like 10-K or IR, nor is it a standalone audit report or management change. As it is a general regulatory announcement regarding company developments, it falls under the RNS category.
2026-03-04 English
Allergy Therapeutics presents progress at AAAAI
Regulatory Filings Classification · 95% confidence The document is a press release announcing Allergy Therapeutics' presentation of scientific progress at the 2026 AAAAI Annual Meeting. It details clinical trial data and research findings but does not contain financial statements or comprehensive financial analysis. It is an announcement of scientific and clinical progress rather than a financial report or regulatory filing. The document is not a report itself but an announcement of participation and presentation at a scientific conference. Therefore, it does not fit into categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. It is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement and does not fit other specific categories.
2026-02-26 English
Update on funding and total voting rights
Regulatory Filings Classification · 98% confidence The document is an official announcement from Allergy Therapeutics PLC regarding a new financing facility ('2026 Hayfin Facility') and the subsequent issuance of new ordinary shares resulting from the exercise of warrants and subscription rights. It details the capital structure changes, the total voting rights, and the admission of new shares to trading on AIM. While it mentions financing, the primary regulatory nature of the announcement regarding share issuance and total voting rights aligns best with the 'Share Issue/Capital Change' category.
2026-02-23 English
Chief Strategy Officer and Board appointments
Board/Management Information Classification · 100% confidence The document is an official announcement from Allergy Therapeutics PLC regarding the appointment of a new Chief Strategy Officer and an Independent Non-Executive Director. It includes biographical details, professional experience, and required regulatory disclosures under the AIM Rules for Companies. This content directly matches the definition for 'Board/Management Information' (MANG), which covers announcements of changes in the company's board or senior management.
2026-01-30 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.